Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancerSophie Marguet, Chafika Mazouni, Bram L T Ramaekers, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2025
Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme trial: TPEx versus EXTREME as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinomaAldéric M Fraslin, Anne Aupérin, Caroline Even, et al.
Gastroenterologie Clinique Et Biologique|January 2, 2008
Cost of radiofrequency ablation in the treatment of hepatic malignanciesJulia Bonastre, Thierry De Baère, Dominique Elias, et al.
BMC Urology|May 12, 2025
Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohortAldéric Fraslin, Florian Colrat, Maryam Karimi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal originDominique Elias, Jérémie H Lefevre, Julie Chevalier, et al.
Bulletin Du Cancer|July 24, 2002
[Cost of treatment and follow up of breast cancer: a retrospective assessment in a comprehensive cancer centre]Hervé Lilliu, Denise Stevens, Catherine Brun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2014
Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patientsBram L T Ramaekers, Manuela A Joore, Béranger Lueza, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 14, 2023
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphomaBéranger Lueza, Anne Aupérin, Charlotte Rigaud, et al.
Cancers|September 9, 2023
A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE CohortMaryam Karimi, Sebastian Mendez-Pineda, Hélène Blanché, et al.
The Lancet Regional Health. Europe|July 23, 2024
Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort studyAdrien Rousseau, Stefan Michiels, Noémie Simon-Tillaux, et al.
Pageof 5